Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
N/A
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 4(2)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06420804Not ApplicableCompleted

Evaluation of the Safety and Efficacy of an Acne Treatment Device

Role: collaborator

NCT05872256Phase 4Completed

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

Role: lead

NCT06042647Phase 4Completed

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

Role: lead

NCT05278624Phase 2Completed

Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

Role: lead

All 4 trials loaded